NCT00080223 - Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Idiopathic Pulmonary FibrosisPulmonary Fibrosis

Interventions

DRUG

Pirfenidone

up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study

Trial Locations (27)

10016

New York

11746

Huntington Station

14620

Rochester

17601

Lancaster

22003

Annandale

30322

Atlanta

34239

Sarasota

43085

Worthington

60007

Elk Grove Village

63110

St Louis

77005

Houston

78229

San Antonio

83686

Nampa

84604

Provo

85006

Phoenix

91767

Pomona

95119

San Jose

96734

Kailua

96761

Lahaina

97220

Portland

97227

Portland

06520

New Haven

02118

Boston

02132

West Roxbury

10029-6574

New York

75390-8503

Dallas

98310 - 3349

Bremerton